Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy
Open Access
- 28 May 2019
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 321 (20) , 1978-1980
Abstract
Sepsis is a heterogeneous syndrome caused by an unbalanced host response to an infection resulting in organ dysfunction. Sepsis is associated with activation ofKeywords
This publication has 9 references indexed in Scilit:
- Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systemsJournal of Critical Care, 2019
- Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-AnalysisThrombosis and Haemostasis, 2018
- Exploring traditional and nontraditional roles for thrombomodulinBlood, 2018
- Coagulation and sepsisThrombosis Research, 2017
- Disseminated intravascular coagulationNature Reviews Disease Primers, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*Critical Care Medicine, 2013
- Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trialJournal of Thrombosis and Haemostasis, 2006
- Effect of High- and Low-Molecular-Weight Heparins on Thrombin-Thrombomodulin Interaction and Protein C ActivationCirculation, 1998